CA-JUNIPER-NETWORKS
12.12.2023 08:01:36 CET | Business Wire | Press release
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, and NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, today announced that DNA, part of Telenor Group and one of Finland’s leading mobile and fixed communications service providers, has deployed an intent-based networking data center fabric based on Juniper’s innovative automation software plus high-performance hardware and utilizing NEC’s advanced systems integration expertise. DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services. Additionally, Juniper Networks™ QFX Series Switches were chosen to power DNA’s Telco Cloud sites across Finland.
The overall objective for DNA’s data center infrastructure refresh is to enable new revenue-generating services whilst delivering operational efficiencies, together leading to enhanced user experiences. By automating the data center network, DNA can eliminate human error, optimize its technical team’s workload to focus on service creation and simplify first-class service delivery at scale. QFX switches enable low latency networking with high reliability and capacity, the key requirements for delivering various services to mobile users who are looking for high-performance network quality.
Juniper Apstra System: Intent-based Networking
- DNA has selected the Juniper Apstra solution as the data center infrastructure’s foundation: unique, intent-based networking software that simplifies, automates and validates data center design, planning and operations, from Day 0 to Day 2+.
- Apstra is a turnkey multi-vendor automation solution (both hardware- and OS-agnostic), that provides DNA with a unified, real-time view of millions of data center elements, plus their dynamic performance, relationships and interdependencies.
- Apstra’s capabilities bring agility and more reliability to DNA’s network design, build and operations. The entire network management operations will be streamlined, and IT teams will be able to focus more on other priorities.
- With Apstra, DNA can create a set of templates for its data center network built on its desired intent and required business outcomes. Apstra automatically converts this intent into the network configurations and policies necessary to consistently achieve DNA’s defined outcomes.
- The Apstra-enabled network undergoes continuous, closed-loop assurance and self-validation to ensure compliance with the declared intent from the blueprint.
- Using the operational, real-time analytics it constantly generates, Apstra is also able to deliver much faster and highly-accurate root-cause analysis of network issues and mitigation data, helping DNA to maximize its data center and services uptime.
- DNA also deployed Juniper Networks QFX Series Switches across its new data center fabric. The QFX Series complements Apstra in DNA’s network by delivering industry-leading reliability, performance and scalability.
- NEC is the strategic partner for DNA, providing pre-integration consultancy and validation as well as premium level support for Juniper’s solution, leveraging its expert support team of certified engineers.
Supporting Quotes:
“DNA has always been an innovator, using the best technology available to provide new services and better experiences for our customers. Because Finnish businesses are fully committed to digital transformation, and their expectations of our service reliability and quality are extremely high, we knew that we had to up our game in the data center by deploying state-of-the-art automation and networking technology. By working with Juniper and NEC, DNA is able to deliver those first-class user experiences and maintain our reputation.”
- Pekka Jääskeläinen, Vice President, Core & IP Networks, DNA Plc
“As a long-standing partner to the Telenor Group, NEC is honored to help DNA drive higher efficiency, agility, and availability of its data center network with automated solutions alongside our strategic partner Juniper. Based on our wealth of multi-vendor, multi-domain network systems integration capability and best-of-breed ecosystem, provided by NEC’s Center of Excellence (CoE), we will continue delivering transformative networking solutions and services that overcome increasing business challenges and keep our customers ahead of the curve.”
- Masayuki Kayahara, General Manager, Service Provider Solutions Department, NEC
“Apstra helps to de-risk data center networking significantly but also streamlines the operational overhead, making life much easier for pressured operators. Automation drives down the total cost of ownership in DNA’s data centers and frees up talent, all the while enabling it to open up rich new revenue streams via services which can be taken to market quickly and more reliably.”
- Mansour Karam, Group Vice President Products, Cloud Ready Data Center, Juniper Networks
Additional Resources
Blog: DIY Network Automation – a High-cost Operation for Telecom Data Centers
Research Topic: What is Intent-based Networking?
Infographic: The State of Data Center Network Automation
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (formerly Twitter), LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com.
LinkedIn: https://www.linkedin.com/company/nec/
YouTube: https://www.youtube.com/user/NECglobalOfficial
Facebook: https://www.facebook.com/nec.global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206095386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom